Ascentis Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.50 M
- Company Age 5 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 5.20 M
- Revenue Growth 47.22%
- Profit Growth 52.41%
- Ebitda 513.56%
- Net Worth 56.03%
- Total Assets 53.29%
About Ascentis Pharma
Ascentis Pharma Private Limited (APPL) is a Private Limited Indian Non-Government Company incorporated in India on 08 January 2020 (Five years and one month 1 days old ). Its registered office is in Khorda, Odisha, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹5.20 M.
Sakti Dash and Sthita Kar serve as directors at the Company.
Company Details
-
Location
Khorda, Odisha, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U33209OR2020PTC032456
-
Company No.
032456
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
08 Jan 2020
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Cuttack
Industry
Who are the key members and board of directors at Ascentis Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sakti Dash
|
Managing Director | 08-Jan-2020 | Current |
Board Members (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
|
Sthita Kar
|
Director | 09-Dec-2022 | Current |
Financial Performance of Ascentis Pharma.
Ascentis Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 47.22% increase. The company also saw a substantial improvement in profitability, with a 52.41% increase in profit. The company's net worth Soared by an impressive increase of 56.03%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ascentis Pharma?
Unlock access to Ascentis Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
₹5.20 M
₹0
Charges Breakdown by Lending Institutions
- Axis Bank Limited : 0.52 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 07 Oct 2022 | Axis Bank Limited | ₹5.20 M | Open |
How Many Employees Work at Ascentis Pharma?
Ascentis Pharma has a workforce of 22 employees as of Mar 28, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ascentis Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ascentis Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
